Corcept Therapeutics
CORT
96 hedge funds and large institutions have $201M invested in Corcept Therapeutics in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 35 increasing their positions, 23 reducing their positions, and 12 closing their positions.
1,988% more call options, than puts
Call options by funds: $167K | Put options by funds: $8K
52% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
1% less funds holding
Funds holding: 97 → 96 (-1)
6% less capital invested
Capital invested by funds: $215M → $201M (-$13.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$1.59M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$678K |
| 3 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$575K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$505K |
| 5 |
First Eagle Investment Management
New York
|
+$373K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.39M |
| 2 |
Renaissance Technologies
New York
|
-$1.05M |
| 3 |
Millennium Management
New York
|
-$724K |
| 4 |
D.E. Shaw & Co
New York
|
-$644K |
| 5 |
Two Sigma Investments
New York
|
-$376K |
CORT Hedge Fund Activity: Q1 2016 in Review
96 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q1 2016, worth a combined $201M — down 6.5% from $215M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CORT and 11 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 35 added.
The largest buyer was Brandywine Global Investment Management, opening a new position worth an estimated $1.59M. The largest seller was TFS Capital, cutting an estimated $1.39M.
- 96 institutional investors held Corcept Therapeutics (CORT) as of Q1 2016, down from 97 in Q4 2015.
- Funds reported $201M of Corcept Therapeutics stock for Q1 2016, down 6.5% quarter-over-quarter.
- 11 funds opened new Corcept Therapeutics positions in Q1 2016 and 12 closed out, a net change of -1 holder.
- The largest Corcept Therapeutics buyer in Q1 2016 was Brandywine Global Investment Management, an estimated $1.59M added.
- The largest Corcept Therapeutics seller in Q1 2016 was TFS Capital, an estimated $1.39M sold.
Based on aggregated 13F filings for Q1 2016.